Kaposi's sarcoma associated with chronic myeloid leukemia and imatinib mesylate therapy

被引：2
|
作者：
D'Addona, Matteo [1 ]
Pezzullo, Luca [1 ]
Giudice, Valentina [1 ,2 ]
Serio, Bianca [1 ]
Baldi, Carlo [3 ]
Zeppa, Pio [2 ,3 ]
Selleri, Carmine [1 ,2 ]
机构：
[1] Univ Hosp San Giovanni Dio & Ruggi dAragona, Hematol & Transplant Ctr, Salerno, Italy
[2] Univ Salerno, Dept Med Surg & Dent, Baronissi, Italy
[3] Univ Hosp San Giovanni Dio & Ruggi dAragona, Anat Pathol, Salerno, Italy
来源：
CLINICAL CASE REPORTS | 2022年 / 10卷 / 06期
关键词：
BCR-ABL; inhibitor; chronic myeloid leukemia; Kaposi's sarcoma; INTERFERON-ALPHA;
D O I：
10.1002/ccr3.5919
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Kaposi's sarcoma is associated with immunosuppression and human herpesvirus 8 infection, while rarely described in myeloid malignancies. Here, we illustrate a rare case of chronic myeloid leukemia treated with imatinib, a tyrosine kinase inhibitor, who developed a human herpesvirus 8-related Kaposi's sarcoma.
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Results of imatinib mesylate therapy in chronic myeloid leukemia: Experience of a single center
    Pasa, S.
    Boyraz, T.
    Beyaz, C.
    Sayar, S.
    Atayan, Y.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 530 - 530
  • [22] The unfolding story of imatinib mesylate for chronic myeloid leukemia
    Goldman, John M.
    ONCOLOGY-NEW YORK, 2007, 21 (06): : 663 - 664
  • [23] Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia
    Barton, JC
    Jones, SC
    Lamberth, WC
    Reymann, MT
    Scott, VC
    AMERICAN JOURNAL OF HEMATOLOGY, 2002, 71 (02) : 139 - 140
  • [24] Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia
    Kovitz, Craig
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    Abruzzo, Lynne V.
    Cortes, Jorge
    BLOOD, 2006, 108 (08) : 2811 - 2813
  • [25] Iœultiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia
    Galanopoulos, A.
    Papadhimitriou, S. I.
    Kritikou-Griva, E.
    Georgiakaki, M.
    Anagnostopoulos, N. I.
    ANNALS OF HEMATOLOGY, 2009, 88 (03) : 281 - 282
  • [26] Response to imatinib mesylate in late chronic phase chronic myeloid leukemia
    Mukhopadhyay, S.
    Chitalkar, P. G.
    Gupta, P. R.
    Roy, U.
    Mukhopadhyay, A.
    ANNALS OF ONCOLOGY, 2007, 18 : 40 - 41
  • [27] Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase
    Linga, Vijay Gandhi
    Ganta, Ranga Raman
    Kalpathi, Krishnamani Iyer
    Gundeti, Sadashivudu
    Rajappa, Senthil J.
    Digumarti, Raghunadharao
    Paul, Tara Roshni
    Tandon, Ashwani
    SOUTH ASIAN JOURNAL OF CANCER, 2014, 3 (04) : 203 - 205
  • [28] Imatinib mesylate (Gleevec®/Glivec®):: A new therapy for chronic myeloid leukemia and other malignancies
    Hernández-Boluda, JC
    Cervantes, F
    DRUGS OF TODAY, 2002, 38 (09) : 601 - 613
  • [29] PROANGIOGENIC CYTOKINES IN CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB MESYLATE
    Kotlyarchuk, K.
    Lukavetsky, L.
    Danysh, O.
    Lukjanova, A.
    Kolisnyk, M.
    Maslyak, Z.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 349 - 349
  • [30] Alterations in Sialylation Patterns are Significantly Associated with Imatinib Mesylate Resistance in Chronic Myeloid Leukemia
    Patel, Kinjal D.
    De, Maitri
    Jethva, Disha D.
    Rathod, Bharati S.
    Patel, Prabhudas S.
    ARCHIVES OF MEDICAL RESEARCH, 2022, 53 (01) : 51 - 58
12345